E xecutives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

In people with HIV infection, new-onset diabetes is independently predicted by higher leukocyte counts — mostly within the ...

Gilead exceeded market expectations in the second quarter, reporting earnings per share of $2.01 on revenue of $7.08 billion. Profitability metrics impressed with a 21.86% margin and a return on ...